Information on EC 3.4.21.B39 - stratum corneum tryptic enzyme and Organism(s) Homo sapiens and UniProt Accession Q9Y337

-

moderate cleavage efficiency

-

?

tert-butyloxycarbonyl-Phe-Ser-Arg-7-amido-4-methylcoumarin + H2O

?

-

best substrate

691153

-

?

tert-butyloxycarbonyl-Phe-Ser-Arg-7-amido-4-methylcoumarin + H2O

tert-butyloxycarbonyl-Phe-Ser-Arg + 7-amino-4-methylcoumarin

-

680225

-

?

tert-butyloxycarbonyl-Val-Pro-Arg-7-amido-4-methylcoumarin + H2O

?

-

best substrate

691153

-

?

Tos-Gly-Pro-Arg-7-amido-4-methyl-coumarin + H2O

Tos-Gly-Pro-Arg + 7-amino-4-methyl-coumarin

-

-

?

Vitronectin + H2O

?

-

cleavage after Arg8

-

?

Z-Gly-Gly-Arg-7-amido-4-methyl-coumarin + H2O

Z-Gly-Gly-Arg + 7-amino-4-methyl-coumarin

-

-

?

additional information

?

-

13 entries

defensin-1alpha + H2O

?

KLK5 is capable of processing defensin-1alpha and may be important in vaginal host defense

-

?

desmocollin-2 + H2O

?

-

-

?

desmocollin-3 + H2O

?

-

-

?

desmoglein protein 1 + H2O

?

-

-

?

mucin 4 + H2O

?

-

-

?

mucin 5B + H2O

?

-

-

?

polypeptide + H2O

peptides

3 entries

proform filaggrin + H2O

mature filaggrin + ?

the enzyme and profilaggrin co-localize in the stratum granulosum in human epidermis. The enzyme interacts with its substrates in granular cells

732104

-

?

desmocollin-3 + H2O

?

-

717412

-

?

desmoglein 1 + H2O

?

-

-

?

additional information

?

-

5 entries

(S)-methyl-1-((3'S,4'S)-4'-(tert-butoxycarbonylamino)-3'-hydroxy-5'-phenylpentanoyl) pyrrolidine-2-carboxylate

-

(S)-methyl-2-((3'S,4'S)-4'-(tert-butoxycarbonylamino)-3'-hydroxy-5'-phenylpentanamido)-3-methylbutanoate

-

(S)-methyl-2-((3'S,4'S)-4'-(tert-butoxycarbonylamino)-3'-hydroxy-5'-phenylpentanamido)-3-phenylpropanoate

-

alpha1-antitrypsin

-

-

alpha2-Macroglobulin

-

-

citrate

-

leupeptin

-

lympho-epithelial Kazal type inhibitor fragment D5

-

-

lympho-epithelial Kazal type inhibitor fragment D6

-

-

lympho-epithelial Kazal type inhibitor fragment D8-D11

-

-

lympho-epithelial Kazal type inhibitor fragment D9-D15

-

-

N-(4-carbamimidoyl-2-fluorophenyl)-2-hydroxybenzamide

pIC50: 5.6, compared to pIC50 for KLK1: 5.5

N-(4-carbamimidoyl-2-methylphenyl)-2-hydroxybenzamide

pIC50: 4.9, compared to pIC50 for KLK1: 5.3

N-(4-carbamimidoyl-3-chlorophenyl)-2-hydroxy-3-methoxybenzamide

pIC50: 5.0, compared to pIC50 for KLK1: 5.9

N-(4-carbamimidoyl-3-fluorophenyl)-2-hydroxy-3-methoxybenzamide

pIC50: 6.0, compared to pIC50 for KLK1: 6.6

N-(4-carbamimidoyl-3-fluorophenyl)-2-hydroxybenzamide

pIC50: 4.7, compared to pIC50 for KLK1: 4.9

N-(4-carbamimidoylphenyl)-1-methyl-1H-benzimidazole-2-carboxamide

PIC50: 3.7, compared to pIC50 for KLK1: 3.7

N-(4-carbamimidoylphenyl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide

pIC50: 3.3, compared to pIC50 for KLK1: 3.3

N-(4-carbamimidoylphenyl)-2,3-dihydroxybenzamide

pIC50: 5.6, compared to pIC50 for KLK1: 5.4

N-(4-carbamimidoylphenyl)-2-hydroxy-3-methoxybenzamide

pIC50: 6.3, compared to pIC50 for KLK1: 6.5

N-(4-carbamimidoylphenyl)-2-hydroxy-3-methylbenzamide

pIC50: 5.1, compared to pIC50 for KLK1: 5.5

N-(4-carbamimidoylphenyl)-2-hydroxybenzamide

PIC50: 5.2, compared to pIC50 for KLK1: 4.9

N-(4-carbamimidoylphenyl)-2-oxopiperidine-3-carboxamide

pIC50: 3.3, compared to pIC50 for KLK1: 3.3

N-(4-carbamimidoylphenyl)-2-oxotetrahydropyrimidine-1(2H)-carboxamide

pIC50: 3.2, compared to pIC50 for KLK1: 3.2

N-(4-carbamimidoylphenyl)-3-chloro-2-hydroxybenzamide

pIC50: 5.6, compared to pIC50 for KLK1: 6.2

N-(4-carbamimidoylphenyl)-3-ethoxy-2-hydroxybenzamide

pIC50: 5.3, compared to pIC50 for KLK1: 6.9

Zn2+

non-competitive inhibition, the enzyme activity is restored by addition of EDTA showing reversibility

8,8'-paepalantine dimer

-

potent competitive inhibitor

alpha2-antiplasmin

-

50% inhibition at 0.8 microM in 0.6 min

-

antithrombin III

-

50% inhibition at 0.8 microM in 6 min

-

chymostatin

-

fukugetin

-

mixed-type inhibitor

752984

leupeptin

-

lymphoepithelial Kazal-type 5 serine protease inhibitor

-

717412

-

paepalantine

-

SPINK9

-

vioxanthin

-

potent competitive inhibitor

Zn2+

-

75% inhibition at 12 nM, 93.5% inhibition at 60 nM, 97.5% inhibition at 120 nM, complete inhibition at 1200 nM

additional information

3 entries

-

androgens

slight up-regulation

647332

-

dermatan

-

estrogen

up-regulaion

heparin

-

progestins

up-regulaion

citrate

-

17% activation at 120 nM, 32% activation at 1200 nM

additional information

no significant effect on enzyme activity by chondroitin

731251

-

0.6

L-Ile-Pro-Arg-p-nitroanilide

0.004

Abz-KLRSSKQ-EDDnp

-

pH and temperature not specified in the publication

0.61

Boc-Gln-Ala-Arg-7-amido-4-methyl-coumarin

-

100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C

1.41

Boc-Gln-Arg-Arg-7-amido-4-methyl-coumarin

-

100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C

0.57

Boc-Gln-Gly-Arg-7-amido-4-methyl-coumarin

-

100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C

0.48

Boc-Leu-Arg-Arg-7-amido-4-methyl-coumarin

-

100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C

0.15

Boc-Leu-GLy-Arg-7-amido-4-methylcoumarin

-

100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C

1.01

Boc-Leu-Lys-Arg-7-amido-4-methyl-coumarin

-

100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C

0.19

Boc-Phe-Ser-Arg-7-amido-4-methyl-coumarin

-

100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C

0.64

Boc-Val-Leu-Lys-7-amido-4-methyl-coumarin

-

100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C

0.02

Boc-Val-Pro-Arg-7-amido-4-methyl-coumarin

-

100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C

1.77

H-Pro-Phe-Ser-Arg-7-amido-4-methyl-coumarin

-

100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C

1.69

Tos-Gly-Pro-Arg-7-amido-4-methyl-coumarin

-

100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C

0.31

Z-Gly-Gly-Arg-7-amido-4-methyl-coumarin

-

100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C

8.5

Abz-KLRSSKQ-EDDnp

-

pH and temperature not specified in the publication

1.78

Boc-Gln-Ala-Arg-7-amido-4-methyl-coumarin

-

100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C

0.41

Boc-Gln-Arg-Arg-7-amido-4-methyl-coumarin

-

100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C

0.18

Boc-Gln-Gly-Arg-7-amido-4-methyl-coumarin

-

100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C

0.31

Boc-Leu-Arg-Arg-7-amido-4-methyl-coumarin

-

100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C

0.07

Boc-Leu-GLy-Arg-7-amido-4-methylcoumarin

-

100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C

0.82

Boc-Leu-Lys-Arg-7-amido-4-methyl-coumarin

-

100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C

2.83

Boc-Phe-Ser-Arg-7-amido-4-methyl-coumarin

-

100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C

0.08

Boc-Val-Leu-Lys-7-amido-4-methyl-coumarin

-

100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C

3.28

Boc-Val-Pro-Arg-7-amido-4-methyl-coumarin

-

100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C

0.47

H-Pro-Phe-Ser-Arg-7-amido-4-methyl-coumarin

-

100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C

0.35

Tos-Gly-Pro-Arg-7-amido-4-methyl-coumarin

-

100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C

0.04

Z-Gly-Gly-Arg-7-amido-4-methyl-coumarin

-

100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C

2125

Abz-KLRSSKQ-EDDnp

-

pH and temperature not specified in the publication

0.00013

(S)-methyl-1-((3'S,4'S)-4'-(tert-butoxycarbonylamino)-3'-hydroxy-5'-phenylpentanoyl) pyrrolidine-2-carboxylate

pH 7.5, 37°C

0.00013

(S)-methyl-2-((3'S,4'S)-4'-(tert-butoxycarbonylamino)-3'-hydroxy-5'-phenylpentanamido)-3-methylbutanoate

pH 7.5, 37°C

0.00012

(S)-methyl-2-((3'S,4'S)-4'-(tert-butoxycarbonylamino)-3'-hydroxy-5'-phenylpentanamido)-3-phenylpropanoate

pH 7.5, 37°C

0.0017

leupeptin

at 25°C in 0.2 M NaCl, 0.1 M Tris-HCl (pH 8.0), and 9% (w/v) Me2SO

0.0000328

lympho-epithelial Kazal type inhibitor fragment D5

-

-

0.0000833

lympho-epithelial Kazal type inhibitor fragment D6

-

-

0.0000037

lympho-epithelial Kazal type inhibitor fragment D8-11

-

-

0.0001187

lympho-epithelial Kazal type inhibitor fragment D9-15

-

-

0.002 - 0.008

Zn2+

0.0244

8,8'-paepalantine dimer

-

pH and temperature not specified in the publication

0.00107

alpha2-antiplasmin

-

-

0.0091

antithrombin III

-

-

0.0475

paepalantine

-

pH and temperature not specified in the publication

0.000065

serine protease inhibitor Kazal type 9

-

693503

-

0.000257

SPINK9

-

pH 8, 21°C

694829

-

0.0229

vioxanthin

-

pH and temperature not specified in the publication

0.000122

(S)-methyl-1-((3'S,4'S)-4'-(tert-butoxycarbonylamino)-3'-hydroxy-5'-phenylpentanoyl) pyrrolidine-2-carboxylate

Homo sapiens

pH 7.5, 37°C

0.000115

(S)-methyl-2-((3'S,4'S)-4'-(tert-butoxycarbonylamino)-3'-hydroxy-5'-phenylpentanamido)-3-methylbutanoate

Homo sapiens

pH 7.5, 37°C

0.000112

(S)-methyl-2-((3'S,4'S)-4'-(tert-butoxycarbonylamino)-3'-hydroxy-5'-phenylpentanamido)-3-phenylpropanoate

Homo sapiens

pH 7.5, 37°C

0.009

Zn2+

Homo sapiens

in 150 mM NaCl, 20 mM HEPES, 0.04 mM imidazole, 0.005% (v/v) Tween 20, at pH 7.0

0.0729

8,8'-paepalantine dimer

Homo sapiens

-

pH and temperature not specified in the publication

0.0125

fukugetin

Homo sapiens

-

at pH 7.5 and 37°C

752984

0.3674

paepalantine

Homo sapiens

-

pH and temperature not specified in the publication

0.0537

vioxanthin

Homo sapiens

-

pH and temperature not specified in the publication

7.5

8

assay at

8

-

37

from ovarian cancer patients

level of KLK 5 peaks around 4 days post ovulation

-

of plantar skin

-

-

-

-

ovarian carcinoma cell

prostate cancer cell line

gene overexpression in a subset of more aggressive ovarian tumors

-

-

-

KLK5 peaks slightly at mid-cycle and shows a major peak at day 25 of menstrual cycle

-

-

female and male

enzyme expression

-

-

-

-

lexpression

breast cancer cell line

-

-

-

keratinocyte cell line

oral squamous cell carcinoma cell

-

pre-malignant keratinocyte cell line

-

-

-

-

high expression

-

-

ovary

-

low expression

ovary cancer cell

ovary cancer cell line

-

high expression

pancreatic cancer cell line

-

high expression

placenta

-

low expression

prostate cancer cell line

-

high expression

prostate gland

renal cell carcinoma cell

-

decreased immunohistochemical expression compared to normal cells

670981

salivary gland

-

high expression

-

-

-

expression

stratum corneum

-

669753, 680225, 691153

-

-

-

expression

trachea

urinary bladder carcinoma cell line

-

-

malfunction

malfunction

physiological function

additional information

potential role of endogenous KLK5 expression in supporting CaP cells to cope with the cytostatic phenomena induced by chemotherapeutic agents practiced in standard first-line CaP chemotherapy

Q9Y337 pBLAST

KLK5_HUMAN

293

0

32020

Swiss-Prot

Show Sequence

-

28000

recombinant deglycosylated enzyme, gel filtration

30000

33000

about, native and recombinant enzyme, gel filtration

40000

native glycosylated enzyme, gel filtration

26000

-

calculated from sequence

monomer

glycoprotein

3 entries

proteolytic modification

can be processed to active enzyme from inactive precursor by trypsin

glycoprotein

crystallized in complex with leupeptin, sitting drop vapour diffusion method with 0.2 M ammonium sulfate, 0.1 M Mes (pH 5.6) and 30% (w/v) PEG monomethyl ether 500

crystals were grown by sitting drop vapour diffusion

-

-

additional information

isopropanol

25%, denaturation

n-propanol

25%, denaturation

from epidermis

heparin-Sepharose column chromatography and benzamidine-Sepharose column chromatography

recombinant as His-tagged enzyme from Escherichia coli BL21(DE3)

647354

recombinant enzyme from CHO-CCL-61 cells and from Pichia pastoris

recombinant from CHO-K1 cells

reversed phase chromatography

-

665944

two chromatography steps, 95% purity

-

cloned from a keratinocyte library, DNA sequence determination and analysis, expression in CHO-K1 cells via infection with Semliki Forest Virus system

cloned from RNA isolated from HaCaT cells, expression as His-tagged enzyme in Escherichia coli BL21(DE3)

647354

DNA sequence determination and analysis, expression in CHO-CCL-61 cells, in Escherichia coli, and in Pichia pastoris

expressed in a baculovirus-insect cell system

expressed in insect cells

680680

gene KLK5, genetic organization and structure of the kallikrein gene family, clustered on chromosome 19q13.3-q13.4

647332

KLK5 quantitative real-time PCR expression analysis

recombinant KLK5 protein is generated from a recombinant baculovirus using the BAC-TO-BAC system (pFastBac_hKLK5_6His-Q-FLAG) expressed in 5L of Spodoptera frugiperda Super 9 insect cells

expressed in insect cell/baculovirus expression system

-

expression in Pichia pastoris

-

gene KLK5, located at the chromosomal locus 19q13.3-q13.4, quantitative real-time PCR expression analysis, 10 transcription factors as potential regulators were found on the control regions of both KLK5 and KLK7

-

overexpression in OV-MZ-6 cancer cell line inoculated into the peritoneal cavity of nude mice promotes tumor growth in mice

-

664273

KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone

the enzyme is upregulated in some types of cancers, mainly prostate and ovarian cancers

731251

10 transcription factors as potential regulators are found on the control regions of both KLK5 and KLK7

-

expression of kallikrein 5 is higher in oral squamous cell carcinoma cell compared to pre-malignant cells

-

kallikrein 5 has increased activity levels in eczematous lesions

-

diagnostics

medicine

diagnostics

-

KLK5 is a potential biomarker for breast cancer

395498

Boeckmann, B.; Bairoch, A.; Apweiler, R.; Blatter, M.C.; Estreicher, A.; Gasteiger, E.; Martin M.J.; Michoud, K.; O'Donovan, C.; Phan, I.; Pilbout, S.; Schneider, M.

The SWISS-PROT protein knowledgebase and its supplement TrEMBL

Nucleic Acids Res.

31

365-370

2003

Homo sapiens (Q9Y337), Mus musculus (P15945)

12520024

647332

Yousef, G.M.; Diamandis, E.P.

The new human tissue kallikrein gene family: structure, function, and association to disease

Endocr. Rev.

22

184-204

2001

Homo sapiens (Q9Y337)

11294823

Brattsand, M.; Egelrud, T.

Purification, molecular cloning, and expression of a human stratum corneum trypsin-like serine protease with possible function in desquamation

J. Biol. Chem.

274

30033-30040

1999

Homo sapiens (Q9Y337), Homo sapiens

10514489

647354

Ekholm, I.E.; Brattsand, M.; Egelrud, T.

Stratum corneum tryptic enzyme in normal epidermis: a missing link in the desquamation process?

J. Invest. Dermatol.

114

56-63

2000

Homo sapiens (Q9Y337), Homo sapiens

10620116

Yousef, G.M.; Kapadia, C.; Polymeris, M.E.; Borgono, C.; Hutchinson, S.; Wasney, G.A.; Soosaipillai, A.; Diamandis, E.P.

The human kallikrein protein 5 (hK5) is enzymatically active, glycosylated and forms complexes with two protease inhibitors in ovarian cancer fluids

Biochim. Biophys. Acta

1628

88-96

2003

Homo sapiens (Q9Y337), Homo sapiens

12890555

664273

Prezas, P.; Arlt, M.J.; Viktorov, P.; Soosaipillai, A.; Holzscheiter, L.; Schmitt, M.; Talieri, M.; Diamandis, E.P.; Krueger, A.; Magdolen, V.

Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells

Biol. Chem.

387

807-811

2006

Homo sapiens

16800744

665944

Caubet, C.; Jonca, N.; Brattsand, M.; Guerrin, M.; Bernard, D.; Schmidt, R.; Egelrud, T.; Simon, M.; Serre, G.

Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7

J. Invest. Dermatol.

122

1235-1244

2004

Homo sapiens

15140227

Michael, I.P.; Sotiropoulou, G.; Pampalakis, G.; Magklara, A.; Ghosh, M.; Wasney, G.; Diamandis, E.P.

Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression

J. Biol. Chem.

280

14628-14635

2005

Homo sapiens

15713679

Michael, I.P.; Pampalakis, G.; Mikolajczyk, S.D.; Malm, J.; Sotiropoulou, G.; Diamandis, E.P.

Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression

J. Biol. Chem.

281

12743-12750

2006

Homo sapiens

16517595

669753

Komatsu, N.; Tsai, B.; Sidiropoulos, M.; Saijoh, K.; Levesque, M.A.; Takehara, K.; Diamandis, E.P.

Quantification of eight tissue kallikreins in the Stratum corneum and sweat

J. Invest. Dermatol.

126

925-929

2006

Homo sapiens

16456535

Kurlender, L.; Yousef, G.M.; Memari, N.; Robb, J.D.; Michael, I.P.; Borgono, C.; Katsaros, D.; Stephan, C.; Jung, K.; Diamandis, E.P.

Differential expression of a human kallikrein 5 (KLK5) splice variant in ovarian and prostate cancer

Tumour Biol.

25

149-156

2004

Homo sapiens

15361712

Yousef, G.M.; White, N.M.; Kurlender, L.; Michael, I.; Memari, N.; Robb, J.D.; Katsaros, D.; Stephan, C.; Jung, K.; Diamandis, E.P.

The kallikrein gene 5 splice variant 2 is a new biomarker for breast and ovarian cancer

Tumour Biol.

25

221-227

2005

Homo sapiens

15627884

670981

Petraki, C.D.; Gregorakis, A.K.; Vaslamatzis, M.M.; Papanastasiou, P.A.; Yousef, G.M.; Levesque, M.A.; Diamandis, E.P.

Prognostic Implications of the Immunohistochemical Expression of Human Kallikreins 5, 6, 10 and 11 in Renal Cell Carcinoma

Tumour Biol.

27

1-7

2006

Homo sapiens

16340244

679041

Shinoda, Y.; Kozaki, K.; Imoto, I.; Obara, W.; Tsuda, H.; Mizutani, Y.; Shuin, T.; Fujioka, T.; Miki, T.; Inazawa, J.

Association of KLK5 overexpression with invasiveness of urinary bladder carcinoma cells

Cancer Sci.

98

1078-1086

2007

Homo sapiens

17459052

680225

Voegeli, R.; Rawlings, A.V.; Doppler, S.; Heiland, J.; Schreier, T.

Profiling of serine protease activities in human stratum corneum and detection of a stratum corneum tryptase-like enzyme

Int. J. Cosmet. Sci.

29

191-200

2007

Homo sapiens

18489349

680680

Debela, M.; Magdolen, V.; Schechter, N.; Valachova, M.; Lottspeich, F.; Craik, C.S.; Choe, Y.; Bode, W.; Goettig, P.

Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences

J. Biol. Chem.

281

25678-25688

2006

Homo sapiens (Q9Y337)

16740631

Debela, M.; Goettig, P.; Magdolen, V.; Huber, R.; Schechter, N.M.; Bode, W.

Structural basis of the zinc inhibition of human tissue kallikrein 5

J. Mol. Biol.

373

1017-1031

2007

Homo sapiens (Q9Y337), Homo sapiens

17881000

Deraison, C.; Bonnart, C.; Lopez, F.; Besson, C.; Robinson, R.; Jayakumar, A.; Wagberg, F.; Brattsand, M.; Hachem, J.P.; Leonardsson, G.; Hovnanian, A.

LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction

Mol. Biol. Cell

18

3607-3619

2007

Homo sapiens (Q9Y337)

17596512

Shaw, J.L.; Petraki, C.; Watson, C.; Bocking, A.; Diamandis, E.P.

Role of tissue kallikrein-related peptidases in cervical mucus remodeling and host defense

Biol. Chem.

389

1513-1522

2008

Homo sapiens (Q9Y337)

18844451

691153

Debela, M.; Beaufort, N.; Magdolen, V.; Schechter, N.M.; Craik, C.S.; Schmitt, M.; Bode, W.; Goettig, P.

Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7

Biol. Chem.

389

623-632

2008

Homo sapiens

18627343

691861

Korbakis, D.; Gregorakis, A.K.; Scorilas, A.

Quantitative analysis of human kallikrein 5 (KLK5) expression in prostate needle biopsies: an independent cancer biomarker

Clin. Chem.

55

904-913

2009

Homo sapiens (Q9Y337), Homo sapiens

19299547

692566

Pettus, J.R.; Johnson, J.J.; Shi, Z.; Davis, J.W.; Koblinski, J.; Ghosh, S.; Liu, Y.; Ravosa, M.J.; Frazier, S.; Stack, M.S.

Multiple kallikrein (KLK 5, 7, 8, and 10) expression in squamous cell carcinoma of the oral cavity

Histol. Histopathol.

24

197-207

2009

Homo sapiens

19085836

693503

Brattsand, M.; Stefansson, K.; Hubiche, T.; Nilsson, S.K.; Egelrud, T.

SPINK9: A selective, skin-specific Kazal-type serine protease inhibitor

J. Invest. Dermatol.

129

1656-1665

2009

Homo sapiens

19194479

694829

Meyer-Hoffert, U.; Wu, Z.; Schroeder, J.M.

Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor

PLoS ONE

4

e4372

2009

Homo sapiens

19190773

Mavridis, K.; Talieri, M.; Scorilas, A.

KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone

Biol. Chem.

391

467-474

2010

Homo sapiens (Q9Y337)

20128692

Li, X.; Liu, J.; Wang, Y.; Zhang, L.; Ning, L.; Feng, Y.

Parallel underexpression of kallikrein 5 and kallikrein 7 mRNA in breast malignancies

Cancer Sci.

100

601-607

2009

Homo sapiens

19453546

Teixeira, T.S.; Freitas, R.F.; Abrahao, O.; Devienne, K.F.; de Souza, L.R.; Blaber, S.I.; Blaber, M.; Kondo, M.Y.; Juliano, M.A.; Juliano, L.; Puzer, L.

Biological evaluation and docking studies of natural isocoumarins as inhibitors for human kallikrein 5 and 7

Bioorg. Med. Chem. Lett.

21

6112-6115

2011

Homo sapiens

21903387

717412

Britland, S.; Hoyle, M.

Transcriptional gene silencing of kallikrein 5 and kallikrein 7 using siRNA prevents epithelial cell detachment induced by alkaline shock in an in vitro model of eczema

Biotechnol. Prog.

28

485-489

2011

Homo sapiens

22095688

Jiang, R.; Shi, Z.; Johnson, J.J.; Liu, Y.; Stack, M.S.

Kallikrein-5 promotes cleavage of desmoglein-1 and loss of cell-cell cohesion in oral squamous cell carcinoma

J. Biol. Chem.

286

9127-9135

2011

Homo sapiens

21163944

731251

De Souza, L.; M. Melo, P.; Paschoalin, T.; Carmona, A.; Kondo, M.; Hirata, I.; Blaber, M.; Tersariol, I.; Takatsuka, J.; Juliano, M.; Juliano, L.; Gomes, R.; Puzer, L.

Human tissue kallikreins 3 and 5 can act as plasminogen activator releasing active plasmin

Biochem. Biophys. Res. Commun.

433

333-337

2013

Homo sapiens (Q9Y337)

23500465

732104

Sakabe, J.; Yamamoto, M.; Hirakawa, S.; Motoyama, A.; Ohta, I.; Tatsuno, K.; Ito, T.; Kabashima, K.; Hibino, T.; Tokura, Y.

Kallikrein-related peptidase 5 functions in proteolytic processing of profilaggrin in cultured human keratinocytes

J. Biol. Chem.

288

17179-17189

2013

Homo sapiens (Q9Y337), Homo sapiens

23629652

752984

Santos, J.A.; Kondo, M.Y.; Freitas, R.F.; dos Santos, M.H.; Ramalho, T.C.; Assis, D.M.; Juliano, L.; Juliano, M.A.; Puzer, L.

The natural flavone fukugetin as a mixed-type inhibitor for human tissue kallikreins

Bioorg. Med. Chem. Lett.

26

1485-1489

2016

Homo sapiens

26848109

White, G.V.; Edgar, E.V.; Holmes, D.S.; Lewell, X.Q.; Liddle, J.; Polyakova, O.; Smith, K.J.; Thorpe, J.H.; Walker, A.L.; Wang, Y.; Young, R.J.; Hovnanian, A.

Kallikrein 5 inhibitors identified through structure based drug design in search for a treatment for Netherton Syndrome

Bioorg. Med. Chem. Lett.

29

821-825

2019

Homo sapiens (Q9Y337)

30691925